Synergistic mechanisms by which sirolimus and cyclosporin inhibit rat heart and kidney allograft rejection

Clinical and Experimental Immunology

Volumn 108, Issue 1, 1997, Pages 63-68

  Stepkowski, S M ^a   Tian, L ^a   Napoli, K L ^a   Ghobrial, R ^a   Wang, M E ^a   Chou, T C ^b   Kahan, B D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cyclosporin; Immunosuppression; Rapamycin; Sirolimus; Synergism

Indexed keywords

CYCLOSPORIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; MESSENGER RNA; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GRAFT REJECTION; HEART TRANSPLANTATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

EID: 0030894459     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1997.d01-984.x     Document Type: Article

References (30)

1. Rideout DC, Chou T-C. Introduction. In: Chou T-C, Rideout DC, eds. Synergism, antagonism, and potentiation in chemotherapy. San Diego: Academic Press, Inc., 1991:3-53.
2. Vathsala A, Chou T-C, Kahan BD. Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation. Transplantation 1990; 49:463-72.
3. Vathsala A, Goto S, Yoshimura N, Stepkowski SM, Chou T-C, Kahan BD. The immunosuppressive antagonism of low doses of FK506 and cyclosporine. Transplantation 1991; 52:121-8.
4. Hakala TR, Starzl TE, Rosenthal YT, Shaw BW, Iwatsuki S. Cadaveric renal transplantation with cyclosporine and steroids. Transplant Proc 1983; 15:465-70.
5. Lindholm A, Albrechtsen D, Tufveson G, Karlberg I, Persson NH, Groth C-G. A randomized trial of cyclosporine and prednisone vs. cyclosporine, azathioprine, and prednisolone in primary cadaveric renal transplantation. Transplantation 1992; 54:624-31.
6. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataraman R, Jain A. FK506 for liver, kidney and pancreas transplantation. Lancet 1989; 2:1000-4.
7. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22, 989), A new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975; 28:721-6.
8. Martel RR, Klicius Y, Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 1977; 55:48-51.
9. Douros J, Suffness M. New antitumor substances of natural origin. Cancer Treat Rev 1981; 8:63-87.
10. Calne RY, Collier DS, Lim S et al. Rapamycin for immunosuppression in organ allografting [Letter]. Lancet 1989; 2:227.
11. Morris RE, Meiser BM. Identification of a new pharmacologic action for an old compound [Letter]. Med Sci Res 1989; 17:877-8.
12. Morris RE, Wu J, Shorthouse R. A study of the contrasting effects of cyclosporine, FK506 and rapamycin on the suppression of allograft rejection. Transplant Proc 1990; 22:1638-41.
13. Granger DK, Cromwell JW, Chen SC et al. Prolongation of renal allograft survival in large animal model by oral Rapamycin monotherapy. Transplantation 1995; 59:183-6.
14. Stepkowski SM, Chen H, Daloze P, Kahan BD. Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney and small bowel transplantation in the rat. Transplantation 1991; 51:22-26.
15. Kahan BD, Gibbons S, Tejpal N, Stepkowski SM, Chou T-C. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation 1991; 51:232-9.
16. Tu Y, Stepkowski SM, Chou T-C, Kahan BD. The synergistic effects of cyclosporine, sirolimus, and brequinar on heart allograft survival in mice. Transplantation 1995; 27:177-83.
17. Martin DF, Debarge LR, Nussenblatt RB, Chan C-C, Roberge FG. Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis. J Immunol 1995; 154:922-7.
18. Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66:807-15.
19. Henderson DJ, Naya I, Bundick RV, Smith GM, Schmidt JA. Comparison of the effects of FK506, cyclosporine and rapamycin on IL-2 production. Immunology 1991; 73:316-21.
20. Napoli KL, Kahan BD. Sample clean-up and high performance liquid chromatographic techniques for measurements of whole blood rapamycin concentrations. J Chromatography B 1994; 654:111-20.
21. Ono K, Lindsey ES. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg 1969; 517:225-9.
22. Fisher B, Lee S. Microvascular surgical techniques in research: special reference to renal transplantation in the rat. Surgery 1965; 58:904-14.
23. Knight R, Ferraresso M, Serino F, Katz S, Lewis R, Kahan BD. Brief communication: low dose rapamycin potentiates the effects of subtherapeutic doses of cyclosporine to prolong renal allograft survival in the mongrel canine model. Transplantation 1993; 55:947-9.
24. Yakimets WJ, Leakey JR, Yatscoff RW et al. Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporine therapy at low doses. Transplantation 1993; 56: 1293-8.
25. Kahan BD. Sirolimus: a new agent for clinical renal transplantation. Transplant Proc 1997; in press.
26. Jain J, McCaffrey PG, Miner Z et al. The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun. Nature 1993; 365:352-5.
27. 70S6 kinase. Nature 1992; 358:70-73.
28. 1/S phase growth arrest in T-lymphocytes. J Biol Chem 1993; 268:3734-8.
29. Kipl cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994; 372:570-3.
30. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996; 14:483-510.